Composition and method for treating penile erectile dysfunction
CA 2296373 C · Owner: Krauser, Scott F. · Inventors: Gyurik, Robert J.; Samour, Carlos M.; Krauser, Scott F.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A composition for the topical transdermal administration to the penis is based on prostaglandin E1. The composition is non-irritating and effective for relieving erectile impotence or other penile erectile dysfunction. A penetration enhancing effective amount of a dioxolane dioxane, or acetal skin penetration enhancing compound in a pharmaceutically acceptable aqueous alcoholic carrier is used to facilitate the penetration of the prostaglandin E1 active ingredient through the skin. Phentolamine or prazosin may be used in combination with or in I place of prostaglandin E1.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 15, 1998 and granted August 12, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 15, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 15, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.